ALKEM LABORATORIES LTD. (ALKEM) financials

ALKEM LABORATORIES LTD. (ALKEM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Market Cap: ₹60,380Cr.
Current Price: ₹5,050
Stock P/E: 26.9
ROE: 18.2%
ROCE: 19.9%
Book Value: ₹1,171
Dividend Yield: 1.05%
52W High / Low: ₹5,934/5,042

In Jun 2026, ALKEM LABORATORIES LTD. (ALKEM) reported sales ₹2,668 Cr and net profit ₹570 Cr.

Annual TTM: sales ₹9,959 Cr, net profit ₹2,196 Cr.

Shareholding: Promoters 49.70% (Sep 2026), FIIs 10.32% (Sep 2026), DIIs 22.83% (Sep 2026), Public 17.14% (Sep 2026), No. of Shareholders 62,555% (Sep 2026).

ALKEM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	2,355	2,287	2,045	2,372	2,542	2,491	2,258	2,668
Expenses	1,714	1,629	1,748	1,752	1,771	1,802	1,914	1,931
Operating Profit	640	658	297	620	771	689	344	737
OPM %	27%	29%	15%	26%	30%	28%	15%	28%
Other Income	176	216	163	165	164	93	86	137
Interest	17	21	17	13	13	16	16	18
Depreciation	61	68	92	59	59	61	78	57
Profit before tax	738	785	351	714	864	706	336	798
Tax %	5%	8%	21%	8%	9%	12%	35%	29%
Net Profit	698	723	277	656	787	622	217	570
EPS in Rs	58.34	60.48	23.16	54.88	65.80	52.03	18.15	47.67
Raw PDF	—	—	—	—	—	—	—	—

ALKEM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	6,677	7,220	8,830	9,055	7,964	8,813	9,664	9,959
Expenses	5,209	5,268	7,018	7,665	6,290	6,657	7,239	7,419
Operating Profit	1,468	1,951	1,812	1,389	1,674	2,156	2,425	2,540
OPM %	22%	27%	21%	15%	21%	24%	25%	26%
Other Income	96	175	199	254	426	698	509	481
Interest	39	43	38	86	80	76	57	62
Depreciation	187	199	219	230	239	284	257	255
Profit before tax	1,338	1,884	1,753	1,327	1,781	2,495	2,620	2,704
Tax %	6%	11%	12%	15%	2%	9%	13%	—
Net Profit	1,264	1,685	1,541	1,134	1,747	2,281	2,282	2,196
EPS in Rs	105.75	140.93	128.90	94.88	146.13	190.77	190.87	183.65
Dividend Payout %	24%	21%	26%	53%	27%	24%	28%	—

ALKEM balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24	24	24	24	24	24	24	24
Reserves	5,441	6,257	7,602	8,720	9,326	10,531	12,298	13,975
Borrowings	503	1,209	1,384	2,294	1,182	1,005	439	611
Other Liabilities	1,324	1,616	1,763	2,132	2,200	2,478	2,835	2,651
Total Liabilities	7,292	9,106	10,773	13,169	12,731	14,038	15,596	17,261
Fixed Assets	1,606	1,837	1,758	1,882	1,825	1,782	1,591	1,550
CWIP	382	314	323	232	229	91	76	123
Investments	1,696	1,956	2,152	2,529	3,006	2,829	4,407	5,552
Other Assets	3,609	4,999	6,539	8,526	7,672	9,336	9,521	10,037
Total Assets	7,292	9,106	10,773	13,169	12,731	14,038	15,596	17,261

ALKEM cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	745	682	1,324	1,299	1,437	1,687	2,189	1,969
Cash from Investing Activity	-313	-995	-1,121	-1,669	197	-866	-1,007	-1,461
Cash from Financing Activity	-276	173	-209	437	-1,711	-959	-1,037	-673
Net Cash Flow	156	-141	-5	67	-77	-138	145	-165
Free Cash Flow	392	415	1,230	1,065	1,298	1,586	2,003	1,822
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	91%	62%	84%	90%	120%	122%	120%	101%

ALKEM shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	55.66%	55.13%	53.04%	51.20%	51.20%	51.20%	49.70%	49.70%
FIIs	10.14%	9.40%	9.11%	9.47%	9.97%	10.15%	10.42%	10.32%
DIIs	18.01%	19.42%	21.80%	21.93%	21.54%	21.39%	22.64%	22.83%
Public	16.19%	16.05%	16.05%	17.39%	17.30%	17.25%	17.25%	17.14%
No. of Shareholders	84,038	84,326	79,740	67,196	64,536	62,835	62,822	62,555

ALKEM key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	62	85	79	73	71	80	65	59
Inventory Days	159	156	207	202	164	257	196	212
Days Payable	121	116	131	114	103	219	188	192
Cash Conversion Cycle	100	125	155	162	133	119	72	79
Working Capital Days	51	39	45	13	50	171	128	123
ROCE %	17%	20%	23%	18%	13%	16%	20%	20%

ALKEMUpdated 19 Oct 2026, 3:04

Alkem Laboratories Ltd.

ALKEMUpdated 19 Oct 2026, 3:04

Market Cap

₹60,380Cr.

Current Price

₹5,050

High / Low

₹5,934/5,042

Stock P/E

26.9

ROE18.2%

ROCE19.9%

Book Value₹1,171

Face Value₹2.00

Dividend Yield1.05%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	2253	21	1919	65	58	319	15	271	22.7
Sep 2023	2635	19	1980	62	59	639	-1	647	54.07
Dec 2023	2009	21	1517	93	57	508	1	504	42.17
Mar 2024	2365	21	1958	71	69	389	16	325	27.18
Jun 2024	2127	21	1566	144	63	621	6	583	48.78
Sep 2024	2355	17	1714	176	61	738	5	698	58.34
Dec 2024	2287	21	1629	216	68	785	8	723	60.48
Mar 2025	2045	17	1748	163	92	351	21	277	23.16
Jun 2025	2372	13	1752	165	59	714	8	656	54.88
Sep 2025	2542	13	1771	164	59	864	9	787	65.8
Dec 2025	2491	16	1802	93	61	706	12	622	52.03
Mar 2026	2258	16	1914	86	78	336	35	217	18.15
Jun 2026	2668	18	1931	137	57	798	29	570	47.67

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	3072	73	2722	177	60	395	7	368	30.75
Mar 2016	3911	59	3180	240	74	839	17	700	58.56
Mar 2017	4548	24	3668	115	76	894	1	883	73.86
Mar 2018	5281	32	4308	101	108	934	23	716	59.87
Mar 2019	5714	28	4667	66	141	944	15	800	66.9
Mar 2020	6677	39	5209	96	187	1338	6	1264	105.75
Mar 2021	7220	43	5268	175	199	1884	11	1685	140.93
Mar 2022	8830	38	7018	199	219	1753	12	1541	128.9
Mar 2023	9055	86	7665	254	230	1327	15	1134	94.88
Mar 2024	7964	80	6290	426	239	1781	2	1747	146.13
Mar 2025	8813	76	6657	698	284	2495	9	2281	190.77
Mar 2026	9664	57	7239	509	257	2620	13	2282	190.87
TTM	9959	62	7419	481	255	2704	—	2196	183.65

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	49.7%
FIIs	10.32%
DIIs	22.83%
Public	17.14%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	56.74%	8.49%	15.91%	—	18.86%
Mar 2024	56.74%	9.11%	15.63%	—	18.51%
Jun 2024	56.38%	8.69%	18.56%	—	16.37%
Sep 2024	55.66%	9.02%	19.21%	—	16.12%
Dec 2024	55.66%	10.14%	18.01%	—	16.19%
Mar 2025	55.13%	9.4%	19.42%	—	16.05%
Jun 2025	53.04%	9.11%	21.8%	—	16.05%
Sep 2025	51.2%	9.47%	21.93%	—	17.39%
Dec 2025	51.2%	9.97%	21.54%	—	17.3%
Mar 2026	51.2%	10.15%	21.39%	—	17.25%
Jun 2026	49.7%	10.42%	22.64%	—	17.25%
Sep 2026	49.7%	10.32%	22.83%	—	17.14%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	24	3077	1103	657	4861	870	96	1071	2824	4861
Mar 2016	24	3576	380	843	4822	875	147	1158	2644	4822
Mar 2017	24	4369	368	1137	5898	1126	218	1518	3037	5898
Mar 2018	24	4861	548	1381	6814	1471	299	1544	3500	6814
Mar 2019	24	5441	503	1324	7292	1606	382	1696	3609	7292
Mar 2020	24	6257	1209	1616	9106	1837	314	1956	4999	9106
Mar 2021	24	7602	1384	1763	10773	1758	323	2152	6539	10773
Mar 2022	24	8720	2294	2132	13169	1882	232	2529	8526	13169
Mar 2023	24	9326	1182	2200	12731	1825	229	3006	7672	12731
Mar 2024	24	10531	1005	2478	14038	1782	91	2829	9336	14038
Mar 2025	24	12298	439	2835	15596	1591	76	4407	9521	15596
Mar 2026	24	13975	611	2651	17261	1550	123	5552	10037	17261

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	242	-260	26	8
Mar 2016	630	311	-958	-17
Mar 2017	499	-362	-125	13
Mar 2018	318	-273	-60	-15
Mar 2019	745	-313	-276	156
Mar 2020	682	-995	173	-141
Mar 2021	1324	-1121	-209	-5
Mar 2022	1299	-1669	437	67
Mar 2023	1437	197	-1711	-77
Mar 2024	1687	-866	-959	-138
Mar 2025	2189	-1007	-1037	145
Mar 2026	1969	-1461	-673	-165

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	45	45	51	60	62	85	79	73	71	80	65	59
Inventory Days	143	139	175	180	159	156	207	202	164	257	196	212
Days Payable	90	110	139	144	121	116	131	114	103	219	188	192
Cash Conversion Cycle	97	74	86	97	100	125	155	162	133	119	72	79
Working Capital Days	-62	12	29	43	51	39	45	13	50	171	128	123
ROCE %	11%	22%	21%	19%	17%	20%	23%	18%	13%	16%	20%	20%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of ALKEM LABORATORIES LTD. (ALKEM)?

The reported market capitalisation for ALKEM LABORATORIES LTD. (ALKEM) is ₹60,380Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of ALKEM?

The current price shown for ALKEM LABORATORIES LTD. (ALKEM) on Fincrux is ₹5,050 with a 52-week high/low of ₹5,934/5,042.

What is the P/E ratio of ALKEM LABORATORIES LTD. (ALKEM)?

The stock P/E for ALKEM LABORATORIES LTD. (ALKEM) is 26.9 on Fincrux, with ROE at 18.2% and ROCE at 19.9%.

What were ALKEM latest quarterly results?

For Jun 2026, ALKEM LABORATORIES LTD. (ALKEM) reported sales ₹2,668 Cr and net profit ₹570 Cr (figures in ₹ crore unless noted).

What are ALKEM annual sales and net profit?

For TTM, ALKEM LABORATORIES LTD. (ALKEM) shows sales of ₹9,959 Cr and net profit of ₹2,196 Cr on the Fincrux profit & loss statement.

Who owns ALKEM LABORATORIES LTD. (ALKEM)?

Latest shareholding for ALKEM LABORATORIES LTD. (ALKEM) on Fincrux: Promoters 49.70% (Sep 2026), FIIs 10.32% (Sep 2026), DIIs 22.83% (Sep 2026), Public 17.14% (Sep 2026), No. of Shareholders 62,555% (Sep 2026).

Where can I find ALKEM LABORATORIES LTD. (ALKEM) financials?

ALKEM LABORATORIES LTD. (ALKEM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show ALKEM balance sheet and cash flow?

Yes. The ALKEM LABORATORIES LTD. (ALKEM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 3:04